Verizon awarded $34.6M in digital modernization contracts with U.S. DOE » 09:3412/0112/01/21
Verizon Public Sector has…
Verizon works with Bang & Olufsen to launch soundbars with built-in stream TV » 09:1212/0112/01/21
Verizon Stream TV…
Meta selects AWS as 'key', long-term strategic cloud provider » 09:1112/0112/01/21
AMZN, FB, MVRS
Amazon Web Services…
Micron, UMC expand relationship to secure supply chains » 09:0612/0112/01/21
Micron Technology (MU)…
United Airlines to be first to fly aircraft using 100% sustainable fuel » 09:0312/0112/01/21
United will operate an…
Verizon Business adds to NaaS strategy with additions from Cisco » 08:2012/0112/01/21
Verizon Business (VZ)…
Exxon Mobil to maintain capital investments of $20B-$25B through 2027 » 07:2512/0112/01/21
ExxonMobil said it has…
ExxonMobil said it has finalized corporate plans, which increase spending to $15B on greenhouse gas emission-reduction projects over the next six years while maintaining capital investments in its portfolio. The plans support the corporate strategy of continued structural cost savings, investment in low-cost-of-supply and lower-emission products, and further portfolio high-grading, positioning the company to double earnings and cash flow by 2027 versus 2019. The company also announced it is on track to meet its 2025 greenhouse gas emission-reduction plans by year-end 2021, four years ahead of schedule. In addition, ExxonMobil has developed more aggressive plans for further Scope 1 and Scope 2 reductions through 2030, consistent with Paris Agreement pathways. ExxonMobil plans to maintain capital investments in the range of $20B-$25B per year through 2027 with flexibility to adjust to adverse market conditions or changes in policy and technology for low-emissions projects. Projected growth of cash flow and earnings in the Upstream business results from cost reductions and progressing advantaged investments in low-cost-of-supply projects in Guyana, Brazil, and the Permian Basin in the United States. More than 90% of Upstream planned capital investments through 2027 are expected to generate returns of greater than 10% at prices less than or equal to $35 per barrel of oil equivalent, while reducing Upstream GHG emissions intensity by 40%-50% through 2030, compared to 2016 levels. Downstream and Chemical earnings and cash flow growth plans are focused on high-return projects, which are expected to double the volume of performance chemicals and lower-emission fuels and lubricants. The company will leverage its manufacturing scale, integration, and technology position to high-grade its portfolio and reduce costs, while optimizing operations and leveraging the capabilities of the Low Carbon Solutions business to reduce greenhouse gas emission intensity at operated facilities. Increased cash flow and earnings enable both further debt reduction and returns to shareholders. It has also announced a $10B share-repurchase program over 12-24 months that will commence in 2022, and it increased its annual dividend payment for the 39th consecutive year. As part of its plan, ExxonMobil has committed $15B for lower-emission investments through 2027. These investments will include a balance between projects to reduce greenhouse gas emissions from existing operations and increased investments in the Low Carbon Solutions business.
Viatris announces appeals court upholds invalidation of Biogen Tecfidera patent » 07:0412/0112/01/21
Viatris (VTRS) announced…
Viatris (VTRS) announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's (BIIB) Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. The company launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.
Meta cryptocurrency head David Marcus to step down » 06:4312/0112/01/21
In a series of Tuesday…
Sage Therapeutics and Biogen report positive data on depression disorder drug » 06:3412/0112/01/21
Sage Therapeutics (SAGE)…
Sage Therapeutics (SAGE) and Biogen (BIIB) announced 12-month data for the cohort of patients who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months. The SHORELINE Study, part of the LANDSCAPE clinical program, was designed to naturalistically follow adult patients with major depressive disorder - MDD - and evaluate the safety and tolerability of zuranolone as well as the need for repeat dosing for up to one year. For the primary endpoint of safety and tolerability, the data analyzed to date show zuranolone was generally well-tolerated, with no new safety findings or trends identified in the long-term safety data available regardless of the number of courses of zuranolone a patient received. Zuranolone has demonstrated improvements in depressive symptoms and a well-tolerated safety profile throughout the LANDSCAPE clinical program. Secondary endpoints included the percentage of patients who received repeat dosing with zuranolone as well as response and remission as evaluated by the 17-item Hamilton Rating Scale for Depression. In the zuranolone 50 mg cohort, nearly 75% of patients responded to the initial 2-week treatment course. Of those who responded to the initial course and continued in the study, approximately 80% of those patients received at most one additional zuranolone treatment during their time in the study. Enrollment of an anticipated 300 additional patients in the 50 mg cohort is ongoing. The companies plan to present additional data from the ongoing SHORELINE Study in future scientific forums.